Research paperDevelopment of advanced biantibiotic loaded bone cement spacers for arthroplasty associated infections
Graphical abstract
Introduction
The infection associated to arthroplasties is caused by microorganisms that grow and form a “biofilm” (Van De Belt et al., 2001b) in which bacteria are wrapped and protected, achieving a strong adhesion to the surface of the implant (Van de Belt et al., 2001a). When the microorganism density is high, release of molecules that activate other microorganisms can occur contributing to the thickening of the biofilm, phenomenon that is known quorum sensing (Murray et al., 1998). In these cases the efficacy in the antibiotics therapy is drastically decreased. This reduction is also conditioned by the risk of systemic toxicity, which limits the therapeutic doses, and also by the bioavailability of the antibiotic to penetrate in the specific tissue. One of the currently used techniques to eradicate the infection is the two-stage arthroplasty using a temporal antibiotic loaded spacer (Masri et al., 1994). This technique involves the removal of the prosthesis, the filling of the infected cavity with the acrylic bone cement spacer (Anagnostakos et al., 2006) and the re-implantation of a new prosthesis within a period of time of 3 months (Cui et al., 2007, Peng et al., 2011). The acrylic bone cement spacer has demonstrated to reduce the rate of recurrent infection, probably because local antibiotic levels are much higher than those achieved by intravenous or oral therapy, avoiding even the entrance of the antibiotic in blood or urine, and resulting less toxic (Salvati et al., 1986). The implantation of osteo-articular prosthesis has increased noticeably because of the incidence of traumatic accidents and the increase of the average life time. This results in drastic increase of the number of implanted prosthesis and the average time of life of these devices. Also, this is the main cause of the appearance of infections associated to long term implants in such a way that frequently infections appear after 7–10 years, or even longer time of implantation.
The antibiotics currently incorporated to acrylic bone formulations are gentamicin, tobramycin, vancomycin and cephalosporin (Ensing et al., 2008, Lewis, 2009, Neut et al., 2006, Penner et al., 1996). Combinations of two antibiotics are widespread because of the synergistic effect produced on the elution characteristics and the antimicrobial activity of the cement (Penner et al., 1996). Antibiotic loaded poly(methyl methacrylate) (PMMA) bone cements have been applied since long in the treatment of infected arthroplasties and other bone diseases as those appearing in open fractures, infected fractures and chronic osteomyelitis. However, their prolonged used in clinical practice have made microorganisms become more and more resistant to them, i. e. methicillin-resistant S. aureus (MRSA). The prevalence of these increasingly resistant organisms is a major concern to achieve the therapeutic success and also because they can generate cross resistance. Therefore, in the latest years the use of last generation antibiotics is being explored, daptomycin and linezolid playing a relevant role. Daptomycin is a lipopeptide active against gram-positive bacteria including MRSA and S. coagulase-negative. It has a broad spectrum activity, scarce adverse effects and low risk of generating resistance (Critchley et al., 2003, Hall et al., 2004). Linezolid belongs to the group of oxazolidinones, and it is active against gram-positive organisms including resistant enterococci and MRSA (Stefani et al., 2010). It has been successfully used in the treatment of osseous infections such as osteomyelitis and infections associated with arthroplasties (Potoski et al., 2006) and cross resistance to linezolid of gram-positive germs is a rare phenomenon (Tenover et al., 2007, Vardakas et al., 2009).
In the past years, several strategies were attempted to enhance antibiotic elution from acrylic formulations such as alteration of the cement composition and antibiotic loading (Anagnostakos and Kelm, 2009). Some formulations introduced soluble components in the solid phase to increase porosity and hence facilitate elution of the drug (Kuechle et al., 1991). Addition of 25% dextran to a commercial formulation greatly facilitated elution of daptomycin, vancomycin and amikacin. (Kuechle et al., 1991). Release modulators of lactose and hydroxypropylmethylcellulose (HPMC) have been added to the solid phase of gentamicin loaded self-curing bone cements (Virto et al., 2003), controlling elution by the amount of the modulator (Frutos et al., 2010). Loading PMMA self-curing formulations with soluble fillers such as xylitol, glycine (McLaren et al., 2006), sucrose and erythritol (McLaren et al., 2007), enhanced PMMA permeability and elution kinetics. Partially biodegradable acrylic composites containing PMMA/poly(ε-caprolactone) (PCL) beads were prepared for vancomycin release in non-load bearing graft applications (Méndez et al., 2002). Porosity of self-curing systems increased by using only 50% of the prescribed amount of monomer and permeability enhanced by incorporation of gel-forming polymeric filler, i.e. poly(vinyl pyrrolidone) or HPMC. Reduction of the amount of monomer was crucial to obtain a release antibiotic improvement and all biodegradable fillers almost tripled the amount of gentamicin release (Rasyid et al., 2009).
In this work, we consider both the enhancement of antibiotic release of cements and the incorporation of latest generation antibiotics used in clinical practice, that, up to our knowledge has not been reported so far, for application as antibiotic loaded acrylic bone cement spacers in the treatment of recurrent infections.
Therefore, this paper deals with the preparation of advanced acrylic bone cement spacers formulated with biodegradable microparticles of poly(D,L-lactic-co-glycolic) acid copolymer (PLGA) and loaded with combinations of antibiotics, one them being of last generation (daptomycin or linezolid). The paper also reports on in vitro release kinetics and biodegradation. The in vitro antimicrobial activity of formulations was studied using S. aureus as a gram-positive microorganism. Finally, cytotoxicity of cements was tested using cell cultures of human osteoblasts and standardized protocols.
Section snippets
Materials
Palacos R® (Heraeus Medical, Germany) was used as commercial acrylic bone cement. PLGA with D,L-lactide:glycolide molar ratio 50:50 and 0.45-0.60 dl/g intrinsic viscosity in chloroform (0.1%) at 25 °C (Resomer® RG504) was purchased from Evonik. Linezolid (Pfizer, Peapack, USA), daptomycin (Cubist Pharmaceutical Inc, USA), vancomycin (Lab. Normon, Spain), poly(vinyl alcohol) (PVA, Sigma-Aldrich), dichloromethane (Scharlau) and phosphate buffered saline solution pH 7.4 (PBS, Sigma-Aldrich) were
Preparation and characterization of biantibiotic loaded bone cement spacers
The main goal of this work was the preparation of advanced biantibiotic loaded acrylic bone cements for application as spacers in recurrent infected cavities of arthroplasties. Palacos R®, commercially available cement, has been selected to facilitate the protocol for a clinical application in short time. We hypothesized that partial substitution of the acrylic polymer by biodegradable microparticles would contribute to the formation of porous in the bulk cement, increase uptake of liquids and
Conclusions
In summary, this study showed that the modification of Palacos R® with incorporation of PLGA microparticles in biantibiotic bone cement formulations containing either daptomycin/vancomycin or linezolid/vancomycin combinations provided cements with good curing parameters and acceptable mechanical properties to be applied in clinic as partially biodegradable and bioactive bone cement spacers. These formulations had the advantage of providing long term accurate release profiles of last generation
Acknowledgements
Authors thank to The Spanish Ministry of Economy and Competitivity (project MAT2014-51918-C2-1-R) and Spanish SECOT Foundation (Project 2015) for financial support.
References (51)
- et al.
Elimination of barium sulphate from acrylic bone cements: use of two iodine-containing monomers
Biomaterials
(2003) - et al.
Hip contact forces and gait patterns from routine activities
J. Biomech.
(2001) - et al.
Influence of lactose addition to gentamicin-loaded acrylic bone cement on the kinetics of release of the antibiotic and the cement properties
Acta Biomater.
(2010) - et al.
Release of daptomycin from polymethylmethacrylate beads in a continuous flow chamber
Diagn. Microbiol. Infect. Dis.
(2004) - et al.
Injectable self-curing bioactive acrylic-glass composites charged with specific anti-inflammatory/analgesic agent
Biomaterials
(2004) - et al.
Effect of varying surface patterns on antibiotic elution from antibiotic-loaded bone cement
J. Arthroplasty
(1995) - et al.
New aspects of the effect of size and size distribution on the setting parameters and mechanical properties of acrylic bone cements
Biomaterials
(1996) - et al.
Elution characteristics of vancomycin and tobramycin combined in acrylic bone-cement
J. Arthroplasty
(1996) - et al.
Surface roughness, porosity and wettability of gentamicin-loaded bone cements and their antibiotic release
Biomaterials
(2000) - et al.
Staphylococcus aureus biofilm formation on different gentamicin-loaded polymethylmethacrylate bone cements
Biomaterials
(2001)
Gentamicin release from modified acrylic bone cements with lactose and hydroxypropylmethylcellulose
Biomaterials
Enhancement of antibiotic elution from acrylic bone cement
J. Biomed. Mater. Res. Part B: Appl. Biomater.
In vitro evaluation of antibiotic release from and bacteria growth inhibition by antibiotic-loaded acrylic bone cement spacers
J. Biomed. Mater. Res. Part B: Appl. Biomater.
Antibiotic-impregnated PMMA hip spacers: current status
Acta Orthop.
Antimicrobial properties and elution kinetics of linezolid-loaded hip spacers in vitro
J. Biomed. Mater. Res. Part B: Appl. Biomater.
Comparative study of antimicrobial release kinetics from polymethylmethacrylate
Clin. Orthop. Relat. Res
Antibiotic susceptibility testing by a standardized single disk method
Am. J. Clin. Pathol.
In vitro activities of daptomycin-, vancomycin-, and teicoplanin-loaded polymethylmethacrylate against methicillin-susceptible methicillin-resistant, and vancomycin-intermediate strains of Staphylococcus aureus
Antimicrob. Agents Chemother.
Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000–2001
Antimicrob. Agents Chemother.
Antibiotic-impregnated cement spacers for the treatment of infection associated with total hip or knee arthroplasty
J. Bone Joint Surg. Am.
Copal bone cement is more effective in preventing biofilm formation than Palacos R-G
Clin. Orthop. Relat. Res.
On the mechanism of action of vancomycin: inhibition of peptidoglycan synthesis in gaffkya homari
Antimicrob. Agents Chemother.
Treatment of deep infection of the hip associated with massive bone loss
J. Bone Joint Surg. Ser. B
Testing of total hip replacements: endurance tests and stress measurements: part 2: stress measurements. proceedings of the institution of mechanical engineers, part H
J. Eng. Med.
Cited by (24)
Teicoplanin-loaded chitosan-PEO nanofibers for local antibiotic delivery and wound healing
2020, International Journal of Biological MacromoleculesCitation Excerpt :However, it has been reported as a safer drug than vancomycin based on having lower incidence of ototoxicity or nephrotoxicity, better pharmacokinetics and longer half-life. The efficacy of teicoplanin has been reported in a wide variety of tissue infections, such as skin and soft tissue, urinary tract, lower respiratory tract and bone and joint infections [23–25]. Teicoplanin has been formulated in nanocarriers for systemic delivery to overcome antimicrobial resistance [26,27].
Biomechanical testing of bioactive bone cements – a comparison of the impact of modifiers: antibiotics and nanometals
2018, Polymer TestingCitation Excerpt :This cement was factory-modified through the addition of antibiotics (4.20% w/w gentamycin and 2.50% w/w vancomycin) and manually modified with nanosilver (1.00% w/w). Recently, bone cement containing double antibiotics has been the main choice among clinical specialists [27]. Hence it was decided to compare its biomechanical properties with pure, unmodified bone cement.
Experimental study of the application of a new bone cement loaded with broad spectrum antibiotics for the treatment of bone infection
2019, Revista Espanola de Cirugia Ortopedica y TraumatologiaModification of methacrylate bone cement with eugenol – A new material with antibacterial properties
2024, Reviews on Advanced Materials ScienceInjectable systems of chitosan in situ forming composite gel incorporating linezolid-loaded biodegradable nanoparticles for long-term treatment of bone infections
2024, Drug Delivery and Translational ResearchEfficacy of Antibiotic Cement in Preserving Endoplants After Infection With Plate Exposure
2023, Surgical Infections